| Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla. | |
| | |
MedLine Citation:
|
PMID: 19300100 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To determine whether time-resolved magnetic resonance angiography (TR-MRA) with ultra-low-dose gadolinium chelate (1.5-3.0 mL) can reliably detect or rule out hemodynamically significant disease in the carotid-vertebral artery territory. MATERIALS AND METHODS: Hundred consecutive patients (62 women, 38 men, mean age = 56.6 years) underwent both TR-MRA and standard high-resolution contrast-enhanced magnetic resonance angiography (CE-MRA), having been randomized to 1 of 2 groups; group A receiving a contrast dose of 1.5 mL for TR-MRA and group B receiving 3.0 mL. For scoring purposes the arterial system was divided into 21 segments. All TR-MRA and CE-MRA studies were blindly assessed by 2 radiologists for overall image quality, segmental arterial visualization, grading of arterial stenosis/occlusion, and incidence and severity of artifact. TR-MRA findings were directly compared with those of the corresponding CE-MRA examinations. RESULTS: Group A TR-MRA studies were of significantly inferior overall image quality compared with those of the corresponding CE-MRA examinations (P = 0.01 for both observers). In group B, overall image quality was similar for TR-MRA and single-phase CE-MRA examinations. On a segmental basis, a higher number of "insufficient quality" segments were identified in group A TR-MRA studies than in group B. A similar reduction in the incidence of artifacts was observed for group B relative to group A TR-MRA studies. Both groups A and B TR-MRA studies were of high specificity, negative predictive values, and accuracy (>97%). CONCLUSION: Ultra-low dose TR-MRA may be performed with 3 mL of gadolinium chelate with preservation of overall image quality and arterial segmental visualization relative to single phase CE-MRA, whereas a 1.5 mL contrast dose is associated with more suboptimal studies. Nonetheless, even at doses as low as 1.5 mL, TR-MRA can exclude arterial stenosis or occlusion. |
| | |
Authors:
|
Derek G Lohan; Anderanik Tomasian; Roya S Saleh; Aparna Singhal; Mayil S Krishnam; J Paul Finn |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Investigative radiology Volume: 44 ISSN: 1536-0210 ISO Abbreviation: Invest Radiol Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-03-20 Completed Date: 2009-05-26 Revised Date: 2009-11-11 |
Medline Journal Info:
|
Nlm Unique ID: 0045377 Medline TA: Invest Radiol Country: United States |
Other Details:
|
Languages: eng Pagination: 207-17 Citation Subset: IM |
Affiliation:
|
David Geffen School of Medicine at UCLA, Department of Radiological Sciences, Diagnostic Cardiovascular Imaging Section, Los Angeles, CA 90095-7206, USA. derek.lohan@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Carotid Arteries* Carotid Stenosis / diagnosis* Contrast Media* / diagnostic use Female Gadolinium DTPA* Humans Magnetic Resonance Angiography* Male Middle Aged Radiation Dosage Radiographic Image Enhancement Severity of Illness Index Time Factors Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Contrast Media; 80529-93-7/Gadolinium DTPA |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two ...
Next Document: Prehypertension and risk of cardiovascular disease in Chinese adults.